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Abstract: Human intravenous immunoglobulins (IVIg) which con-
tain anti-CD95 antibodies have been proposed to treat toxic epidermal
necrolysis (TEN). Presently, there is no evidence that IVIg reach the
keratinocytes in TEN patients. The aim of this study was to assess the Ig
distribution in the serum, blister fluid and skin of six consecutive TEN
patients treated with IVIg (1 g/kg/day) for 3 days. They were compared
with five TEN patients who only received supportive therapy. In all
patients, IgA, IgM and IgG concentrations were measured in the serum
and blister fluid using an immuno-nephelometric method.
Immunohistochemistry was performed on skin biopsies taken from both
TEN clinically involved and uninvolved skin to search for IgG deposits.
On admission, the IgG concentrations were significantly higher in both
TEN serum and TEN blister fluid compared with their respective IgA
and IgM contents. The IgG, IgA and IgM concentrations in blister fluid
were significantly lower than their respective serum concentrations. The
serum and blister fluid IgG concentrations, but not that of IgA and
IgM, were markedly increased at the completion of the IVIg treatment.
By contrast, they remained unchanged in the TEN patients that were
untreated with IVIg. In the IVIg-treated patients, the IgG intraepider-
mal deposits raised markedly in both TEN-involved and uninvolved
skin. This was not the case in patients who did not receive IVIg. These
results suggest that IVIg perfusions brought a prominent increase in
IgG concentration in the serum, blister fluid and epidermis of both
TEN-involved and clinically uninvolved skin. The presence of poten-
tially protective IgG in TEN epidermis following IVIg treatment could
help limiting the disease progression.
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Introduction
Toxic epidermal necrolysis (TEN) is a rare dis-
ease characterized by extensive destruction of the
epidermis. The mortality rate averages 25–30%
due to septicemia and metabolic changes follow-
ing the loss of epidermal integrity. The generally
recognized cause of TEN is an adverse drug reac-
tion resulting from the specific formation of toxic
drug metabolites, probably in the skin itself. The
reactive drug metabolite(s) exert(s) cytotoxic
effects on keratinocytes. This event is thought
to be mediated by the combination of an increase
in Ca2þ intracellular pool, the formation of reac-
tive oxygen species (ROS) including nitric oxide
(NO) and the activation of both the CD95 and
the TNF-a systems (1,2). An active role has also
been ascribed to T lymphocytes, particularly
CD8þ and NK cells in the epidermis (3).
Macrophages Factor XIIIaþ dendrocytes also
appear to play some pathogenic role in the epi-
dermis and dermis (4). Complex interactions link
these cytotoxic effects leading to massive apop-
tosis in keratinocytes (1).
The current TEN treatments combine suppor-
tive and antiseptic measures. It is recognized that
systemic corticosteroids worsen the prognosis by
increasing the risk of septicemia if given for more
than 48 h (5). Only few TEN cases have been
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treated so far with other drugs, including cyclo-
phosphamide, pentoxifylline, thalidomide and
ciclosporin A (1). A few years ago, another ther-
apeutic approach based on the administration of
high dosages of intravenous immunoglobulins
(IVIg) was proposed to treat TEN patients (6).
The rationale for this treatment was to block
CD95 (Fas), a cell-surface receptor initiating ker-
atinocyte apoptosis in TEN (6). Commercially
available IVIg perfusions consist of Ig prepared
from pooled human plasma (7). They typically
contain more than 95% IgG presenting function-
ally intact Fc-dependent effector functions,
admixed with low amounts of IgA and IgM (7).
The clinical outcome following IVIg treatment of
TEN remains controversial, showing improve-
ment or not, in morbidity and mortality (6,8–13).
Conceptually, failure of IVIg treatment in TEN
may result from low bioavailability of the protec-
tive IgG in the altered skin. This aspect was never
explored until now. Using immunochemistry, we
looked for the presence of IgG in TEN skin
before and after a 3-day IVIg treatment. A con-
trol group was composed of patients treated with
supportive measures only. We also measured the
evolution of the Ig concentrations in the serum




Six patients (four women and two men, mean age 47 years) with
TEN diagnosed following defined clinical criteria (14) were
enrolled in the study (TEN patients). A recent drug intake
was reported in each case. The most probable culprit drug was
identified following an imputability method used for toxic drug
reactions. The salient clinical characteristics of the TEN
patients are presented in Table 1. At baseline, that is before
any specific treatment, TEN blister fluid was collected from taut
lesions of less than 24 h in duration. After centrifugation,
the liquid was stored at 20C until testing. Serum was
simultaneously collected and processed following the same pro-
cedure. In each patient, a 4-mm punch biopsy was performed in
a recent (<24 h) blister and in the apparently uninvolved skin at
least 2 cm apart from a bullous or erythematous lesion. The
patients were placed on fluidized beds and benefited from sup-
portive and antiseptic care measures including daily baths. IVIg
(Multigam1, CAF-DCF/Belgian Red Cross) was administered
daily at a dose of 1 g/kg/body weight for 3 days. The IVIg
batches were not tested for their Ig content.
At completion of the treatment, cutaneous biopsies were
obtained close to the first biopsy sites. Serum and blister fluid
were sampled again. Blister fluid was only collected in two
patients, because blisters were dried or punctured in the other
four.
These samples were compared with similar biological samples
obtained from five other TEN patients (three women and two
men, mean age 45 years) stored since the mid nineties (TEN
controls), a time when IVIg were not used in TEN. These
control patients had received supportive care only, without
any drug considered active in TEN, especially IVIg (Table 1).
Ig concentration measurement
IgA, IgG and IgM concentrations were assessed in the serum
and blister fluid samples using immuno-nephelometry with N
antisera to human Ig (Dade Behring, Marburg, Germany) (15).
Data were expressed in g/l and recorded as medians and ranges.
The paired non-parametric Friedman test was performed as a
single overall test to search for differences among IgG, IgA and
IgM concentrations in the samples of both the serum and the
blister fluid obtained at baseline. The Dunn’s multiple compar-
ison test was performed as a second test if variations were
significantly greater than expected by chance. The Wilcoxon
test was used for paired data about the Ig concentrations in
TEN serum and blister fluid. A P-value lower than 0.05 was
considered significant.
Immunohistochemistry
Biopsies were formalin-fixed for about 24 h and paraffin-
embedded. Serial sections were cut and processed for standard
microscopy and immunohistochemistry (16,17). The three-step
avidin–biotin method was applied to a mouse antihuman IgG
monoclonal antibody (Dakocytomation, Glostrup, Denmark)
used at a 1 : 3000 dilution for a 10-min incubation. The intensity
of IgG-positive immunoreactivity present in a pemphigus-like
pattern was rated on a 5-grade scale (0, absent; 1, minimal; 2,
moderate; 3, dense; 4, widespread). Diffuse intrakeratinocyte
deposits indicating a non-specific cell damage were not taken





% of affected body areas
and outcome (A, alive; D, death)
Duration of the disease
at sampling (days) Probable culprit drug
1-IVIg 43, F 80 A 4 Amoxicillinþ clavulanid acid
2-IVIg 43, M 50 A 7 Telithromycine
3-IVIg 47, F 60 A 7 Indapamide
4-IVIg 18, M 60 A 4 Sertaline
5-IVIg 78, F 50 D 3 Amoxicillin
6-IVIg 51, F 75 A 8 Allopurinol
7-C 32, F 64 A 4 Ibuprofen
8-C 56, F 30 D 5 Oxacillin
9-C 20, M 40 D 2 Maxipim or amikacin or vancomycin
10-C 50, M 80 A 2 Naproxen
11-C 66, F 60 D 6 Phenytoin
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into consideration. For each group (IVIg-treated and TEN
control patients, TEN-involved and clinically uninvolved
skin), a mean epidermal score was established for the IgG
deposits. Patient 3 suffering from lupus erythematosus was
not considered in the immunohistochemical study.
Appropriate positive (pemphigus vulgaris, bullous pemphigoid,
lupus erythematosus) and negative controls (normal skin,
superficial burns, junctional epidermolysis bullosa) were used
for assessing the IgG deposits in the skin tissues.
Results
Ig concentration measurements
The storage duration of the samples was much
shorter in IVIg-treated patients than in TEN
control patients. This might introduce a bias in
the data. Hence, a comparison was made at first
between baseline data of both groups of patients.
It appeared that longer sample storage markedly
decreased the detected IgG and IgA levels in
both the serum and the blister fluid. This pre-
cluded any sound comparisons between the post-
treatment data gained in the two groups of patients.
Upon pooling all baseline data, IgG concentra-
tions were significantly higher (P< 0.0001) than
the IgA and IgM concentrations in both the
serum and the blister fluid (Table 2). The blister
fluid concentrations of all Ig types were signifi-
cantly (P< 0.01) lower than their respective
serum concentrations (Table 2).
At the completion of the IVIg treatment, the
median IgG serum concentration was markedly
increased compared with baseline (Tables 2 and 3).
By contrast, it remained similar in the TEN
control patients (Tables 2 and 3). The IgA and
IgM serum concentrations also remained nearly
unchanged in the IVIg-treated group indicating
the lack of IgA and IgM supply by the IVIg
perfusions. In the control group, both the IgA
and the IgM serum concentrations were also
unmodified after 3 days of disease evolution.
Only two blister fluid samplings were available
for comparison in each patient group (Table 4).
The IgG concentration in blister fluid was mark-
edly increased following the IVIg treatment,
while it remained unchanged in the two control
patients. The IVIg perfusions did not supply the
blister fluid with IgA and IgM (data not shown).
The IgA and IgM blister fluid concentrations
also remained nearly unchanged in the control
patients (data not shown).
Immunohistochemistry
In both groups of TEN patients, some intracyto-
plasmic IgG immunolabeling was present in clus-
tered keratinocytes. This aspect indicating cell
damage was not scored.
At baseline, the mean score of IgG deposits in a
pemphigus-like pattern was discretely higher in
Table 2. Immunoglobulin concentrations (g/l) in toxic epidermal necrolysis
(TEN) serum and blister fluid on patient admission
IgG IgA IgM
Patients Serum Blister Serum Blister Serum Blister
IVIg-treated
1 4.7 1.46 1.08 0.28 0.37 0.1
2 19 6.36 2.52 0.94 0.62 0.2
3 23.3 4.9 2.56 0.53 1.24 0.22
4 18.9 3.57 1.03 0.14 0.50 0.06
5 12 1.01 1.99 0.17 0.4 0.04
6 13.5 2.99 3.74 0.99 0.57 0.4
Median 16.20 3.28 2.25 0.40 0.53 0.15
Controls
7 4.87 1.34 1.23 0.26 0.78 0.18
8 3.73 0.46 0.92 0.06 1.63 0.09
9 13.7 1.15 0.86 0.08 0.18 0.04
10 10.9 1.96 2.58 0.28 3.34 0.25
11 2.15 0.63 0.49 0.06 0.07 0.04
Median 4.87 1.15 0.92 0.08 0.78 0.09
Table 3. Immunoglobulin (Ig) concentrations (g/l) in toxic epidermal necrolysis
(TEN) serum and blister fluid after a 3-day disease evolution
IgG IgA IgM
Patients Serum Blister Serum Blister Serum Blister
IVIg-treated
1 37.2 – 2.8 – 0.3 –
2 21.8 – 4.35 – 0.19 –
3 44.3 – 2.79 – 0.71 –
4 14.3 10.5 0.62 0.56 0.94 0.32
5 28.6 – 3.53 – 0.82 –
6 19.5 11.9 2.4 1.38 0.36 0.12
Median 25.2 2.59 0.53
Controls
7 4.77 0.89 1.33 0.19 0.72 0.07
8 4.59 – 1.23 – 1.68 –
9 14.6 – 1.2 – 0.7 –
10 11.35 – 2.04 – 3.42 –
11 5.49 2.15 1.37 0.49 0.99 0.07
Median 5.49 1.33 0.99















4-IVIg 3.57 10.5 4 3 4 3
6-IVIg 2.99 11.9 1 1 4 4
7-untreated 1.34 0.89 2 2 2 2
11-untreated 0.63 2.15 2 1 2 1
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the epidermal blister roof (2,3) than in unin-
volved skin (1,7) in the IVIg-treated patients.
The same finding was evidenced in the control
groups (2.6 vs. 1.8). In the IVIg group, the IgG
mean score raised significantly and equally at the
completion of the treatment, both in TEN-
damaged epidermis (2.3 vs. 3.7) (Fig. 1a,b) and
in uninvolved skin (1.7 vs. 3.7). In the control
group, there was nearly no change in the IgG
mean score in the blister epidermis (2.6 vs. 2.6)
or uninvolved skin (1.8 vs. 2.0) (Table 5).
Correlation between IgG blister fluid concentration
and immunohistochemical rating
Although only examined in four patients, a cor-
relation between IgG blister fluid concentration
and IgG immunohistochemical score was sug-
gested both in IVIg-treated and in untreated
TEN-involved epidermis after 3 days. This correl-
ation seemed also likely in uninvolved skin
(Table 4). In the IVIg group, the mean increase
in epidermal Ig staining was mainly due to case 6
as case 4 had already intense staining at onset.
Moreover, the mean value could be somewhat
misleading given that only two cases were studied
for this parameter.
Discussion
The composition of the blister fluid in TEN has
not been thoroughly explored so far. Among
other bioactive molecules, we presently show
that TEN blister fluid contains Ig, especially
IgG. In each TEN patient, the Ig content in
serum was significantly higher than in the blister
fluid. Thus, it is inferred that the TEN blister
fluid is a transudate (18). When the TEN epider-
mis is altered, the permeability of the postcapil-
lary venules may be increased in the upper dermis
(19). Some cytokines such as TNF-a (4) and ROS
(20) including NO have been shown to be poten-
tial mediators in TEN pathophysiology. They are
also potent vasodilators (21). The formation of
small interendothelial pores is associated with
increased permeability, and plasma is driven
through these pores into the extravascular
space. Extravasated plasma causes its own
epithelial passage by mechanisms involving an
increased basolateral pressure load on the epithe-
lial cells (19).
Commercially available IVIg preparations con-
sist of intact IgG with a distribution of IgG sub-
classes similar to the normal human serum (7).
Most preparations contain minute amounts of
IgA and IgM (7). Indeed, the IVIg-treated TEN
patients showed a large increase in IgG content
Figure 1. IgG pemphigus-like epidermal deposits before (a) and
after (b) a 3-day intravenous immunoglobulin (IVIg) treatment
in a toxic epidermal necrolysis (TEN) patient. A marked
increase in immunolabeling is shown.
Table 5. Scoring of immunoglobulin (Ig) deposits in the epidermis
At baseline 3 days of evolution
Patients Involved skin Intact skin Involved skin Intact skin
IVIg treated
1 4 3 3 3
2 1 1 3 4
3 1 1 4 4
4 4 3 4 3
5 3 1 4 4
6 1 1 4 4
Mean 2.3 1.7 3.7 3.7
Controls
7 2 2 2 2
8 3 2 3 2
9 3 3 4 4
10 3 1 2 1
11 2 1 2 1
Mean 2.6 1.8 2.6 2.0
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in serum at the completion of the treatment,
while IgA and IgM contents remained unmodi-
fied. In TEN control patients, the serum IgG
concentration remained grossly unchanged after
3 days of evolution of the disease, ruling out any
increased Ig supply by the patient him/herself.
The large difference in the IgG serum concen-
trations in the TEN-treated and control groups
at baseline could be ascribed to the storage con-
ditions of the biological samples. Indeed, the
integrity of the Ig stored at 20C is only guar-
anteed for up to 1 year. Over this conservation
time, the in vitro quantitative determination of
the Ig may be impaired. Such a degradation prob-
ably occurred in the samples of the untreated
patients which were stored for 4–6 years.
In IVIg-treated TEN patients, the concentra-
tion of IgG, but not of IgA and IgM, increased
considerably in the blister fluid at the completion
of IVIg perfusions. In TEN control patients, no
difference was observed in Ig blister fluid concen-
trations. This suggests that IVIg administration is
followed by an increase in supplemented IgG
concentration in TEN blister fluid. This repre-
sents the basic condition to benefit from the ther-
apeutic effect with the IVIg preparation in TEN.
In TEN, IVIg has been shown to inhibit Fas
(CD95)-mediated cell death by blocking the Fas
receptor rather than interacting with Fas ligand
(6). IVIg contains both agonistic and blocking
antibodies against CD95 receptor, thus modulat-
ing the transduction of apoptotic signals into
cells (6,7). However, there are great variations
in Fas-R inhibitory activity due to differences in
anti-Fas antibody content within IVIg batches
(11).
This immunohistochemical findings indicate
that IgG are present in TEN-involved and in
clinically uninvolved skin. After IVIg perfusion,
IgG deposits greatly and equally increase in
TEN-involved and uninvolved skin, indicating
that IgG exudation takes place everywhere in
the epidermis irrespective of the presence of
necrotic keratinocytes. The increase in IgG con-
tent in clinically TEN-uninvolved skin after IVIg
may carry protective effect in these areas, pre-
venting any progression of the epidermal destruc-
tion. In control TEN patients, Ig deposits in the
epidermis remained low and unchanged after 3
days, also indicating that IVIg perfusions permit
to increase Ig concentration in TEN skin.
Moreover, a correlation is suggested between
IgG concentrations in lesion fluids and IgG epi-
dermal deposits. As previously reported in TEN
prominent Ig deposits exhibited a pemphigus-like
pattern, suggesting a possible fixation to the
cytoplasmic membrane of the keratinocytes
(22,23). However, the exact cytoplasmic mole-
cules to which IgG bind in TEN epidermis are
unknown.
In conclusion, IVIg perfusion in TEN patients
resulted in a large increase in IgG concentration
in serum, blister fluid and epidermis in necrotic
and clinically uninvolved skin. This represents
the necessary condition to get a protective effect
of IVIg, especially by carrying blocking antibo-
dies against FasR in the skin. The presence of
potentially protective IgG in clinically unin-
volved TEN skin could have some beneficial
effect on the necrosis progression in these areas.
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